GSK plc 6-K, filed Jun 1, 2022
GSK plc (GSK)
6-K
2022-06-01
For: 2022-06-01
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on June 1, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of June 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 1 June 2022, London UK - LSE announcement
Update: Proposed demerger of the Consumer Healthcare business from
GSK to form Haleon
On 23 June 2021 at its Investor Update, GSK plc ("GSK" or the
"Company") confirmed its intention to separate its Consumer
Healthcare business from the GSK Group to form Haleon plc
("Haleon"), an independent listed company. It is proposed that the
separation will be effected by way of a demerger (the "Demerger")
of at least 80 per cent. of GSK's 68 per cent. holding in the
Consumer Healthcare business to GSK
shareholders. The Consumer Healthcare
business is currently a joint venture between GSK and Pfizer Inc
("Pfizer"), with GSK holding a majority controlling interest of 68
per cent. and Pfizer holding 32 per cent.
GSK today confirms that the Circular in relation to the proposed
Demerger, the consolidation of GSK shares (the "GSK Share
Consolidation") and certain new arrangements with Haleon and Pfizer
to give effect to the Demerger (the "Related Party Transactions"),
as well as the Prospectus in relation to the proposed admission of
the Haleon ordinary shares, have each been submitted to the
Financial Conduct Authority ("FCA") for approval. It is
expected that the Haleon ordinary shares will be admitted to the
Premium listing segment of the Official List of the FCA and
admitted to trading on the Main Market of the London Stock Exchange
on Monday 18 July 2022. Application will also shortly be made to
list American Depositary Shares ("ADSs") representing Haleon
ordinary shares on the New York Stock Exchange
("NYSE")[1].
The proposed Demerger is the most significant corporate change for
GSK in the last 20 years, creating two new leading companies, each
with clear targets for growth and the ability to positively impact
the health and lives of billions of people.
Following the Demerger, GSK will focus purely on
biopharmaceuticals, prioritising investment towards the development
of innovative vaccines and specialty medicines. Its R&D
approach will continue to focus on the science of the immune
system, use of human genetics and advanced technologies. Over the
next five-year period, GSK expects to deliver compound
annual growth in sales
and adjusted operating profit of more than 5 per cent. and more
than 10 per cent., respectively, at constant exchange rates (with
2021 as the base year).
Haleon is a new, world-leader in consumer healthcare with a clear
strategy to outperform and run a responsible business. For
prospective investors, it will offer an exceptional and focused
portfolio of category-leading brands with an attractive footprint
and competitive capabilities; a highly attractive financial profile
of above
market, medium-term annual organic revenue growth of 4 to 6 per
cent. combined with sustainable moderate, adjusted margin expansion
on a constant currency basis, with
strong cash generation and conversion.
The Demerger is conditional on, among other things, the approval by
GSK shareholders of the Demerger, the GSK Share Consolidation and
the Related Party Transactions at a General Meeting, the receipt of
all necessary mandatory governmental/regulatory approvals and the
final approval of the Demerger by the GSK Board.
The General Meeting will be held at the Sofitel London Heathrow,
Terminal 5, London Heathrow Airport, TW6 2GD on Wednesday 6 July
2022 at 2.30 p.m. (UK time). Further details will be set out in the
Circular.
Following completion of the Demerger and listing of Haleon, GSK
intends to carry out the GSK Share Consolidation. This is intended
to provide consistency in the GSK share price pre- and
post-separation (subject to interim market movements), in order to
enable comparability between the Company's earnings per share and
share price with previous periods. GSK intends to announce its
second quarter 2022 results on 27 July 2022 in which the Consumer
Healthcare business will be treated as a discontinued
operation. Alongside this, Haleon will provide a trading
update ahead of publishing its full interim results during
September 2022.
As part of the Demerger, GSK proposes to enter into new
arrangements with Pfizer and Haleon and to amend certain existing
arrangements with Pfizer. Pfizer is a related party of GSK
for the purposes of the Listing Rules by virtue of its 32 per cent.
interest in the Consumer Healthcare business, which means that
these new arrangements constitute related party transactions and
require GSK shareholder approval at the General
Meeting. GSK
shareholder approval is also required in relation to the Demerger,
which, due to its size, qualifies as a "Class 1" transaction for
the purposes of the Listing Rules, and the GSK Share Consolidation.
Further details on Haleon, the Demerger and the Related Party
Transactions are set out later in this release and in the
Circular.
A further announcement will be made once the Circular and the
Prospectus have been approved for publication by the
FCA.
Description of GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
Description of Haleon
Haleon will be a global leader in consumer healthcare with a
focused strategy to deliver sustainable above-market growth and
attractive returns to shareholders; a world-class portfolio of
category-leading brands; an attractive geographic footprint well
placed for growth; competitive capabilities including strong
route-to-market capabilities across all channels; and brand
building and innovation capabilities alongside digital
connectivity, which offers a proposition that combines human
understanding with trusted science.
Haleon's product portfolio is split among five categories: Oral
Health, Pain Relief, VMS, Respiratory Health, Digestive Health and
Other. Haleon's largest category by revenue is Oral Health, which
accounted for 28.5 per cent. of Haleon's revenue in the year ended
31 December 2021. The Pain Relief and Digestive Health and Other
categories also significantly contribute to revenue, respectively
contributing 23.4 per cent. and 20.4 per cent. of revenue in the
year ended 31 December 2021. VMS and Respiratory Health
respectively accounted for 15.7 per cent. and 11.9 per cent. of
revenue in the year ended 31 December 2021.
In the year ended 31 December 2021 the profit before tax
attributable to Haleon was £1,636 million. As at 31 March 2022
the gross assets of Haleon were £45,023 million. On an
unaudited pro forma basis, net debt of Haleon as at 31 March 2022
would have been £10,349 million.[2]
Haleon Designate Board
A new independent board has been appointed specifically to support
the delivery and growth strategy for Haleon, under the leadership
of its Chair Designate, Sir Dave Lewis.
|
Name
|
Position
|
|
Sir
Dave Lewis
|
Non-Executive
Chair**
|
|
Brian
McNamara
|
Chief
Executive Officer
|
|
Tobias
Hestler
|
Chief
Financial Officer
|
|
Manvinder
Singh (Vindi) Banga
|
Senior
Independent Non-Executive Director*
|
|
Marie-Anne
Aymerich
|
Non-Executive
Director*
|
|
Tracy
Clarke
|
Non-Executive
Director*
|
|
Dame
Vivienne Cox
|
Non-Executive
Director*
|
|
Asmita
Dubey
|
Non-Executive
Director*
|
|
Deirdre
Mahlan
|
Non-Executive
Director*
|
|
Bryan
Supran
|
Non-Executive
Director (Pfizer Nominee)*
|
|
John
Young
|
Non-Executive
Director (Pfizer Nominee)*
|
*Appointment to become effective from Admission.
**Sir Dave Lewis was appointed as a director of the company
on 23 May 2022. His appointment as Non-Executive Chair takes effect
on Admission.
Haleon Senior Management
In addition to the Designate Board, the current members of the
senior executive team with responsibility for day-to-day management
of Haleon's business are set out below.
|
Name
|
Position
|
|
Dana
Bolden
|
Head of
Corporate Affairs
|
|
Keith
Choy
|
Head of
Asia Pacific
|
|
Bart
Derde
|
Head of
Quality and Supply Chain
|
|
Amy
Landucci
|
Head of
Digital and Technology
|
|
Filippo
Lanzi
|
Head of
EMEA and LatAm
|
|
Jooyong
Lee
|
Head of
Strategy and Office of the CEO
|
|
Teri
Lyng
|
Head of
Transformation and Sustainability
|
|
Mairéad
Nayager
|
Chief
Human Resources Officer
|
|
Lisa
Paley
|
Head of
US and North America
|
|
Franck
Riot
|
Head of
R&D
|
|
Tamara
Rogers
|
Chief
Marketing Officer
|
|
Bjarne
P Tellmann
|
General
Counsel
|
Description of the Demerger
Structure of the Demerger
The separation will be effected via a demerger of at least 80 per
cent. of GSK's interest in the Consumer Healthcare business to
Haleon plc, a listing of Haleon on the Main Market of the LSE, and
the establishment of a level 2 sponsored American depositary
receipt programme on the NYSE.
Prior to the Demerger, GlaxoSmithKline Consumer Healthcare Holdings
(No. 2) Limited ("JVCo"), the current holding company of the
Consumer Healthcare business, will pay dividends to GSK and Pfizer,
which are expected to result in GSK receiving cash proceeds of more
than £7 billion at separation (the "Pre-Demerger
Dividends"). Qualifying GSK shareholders will be entitled to
receive one Haleon share for each GSK share held by them and will
continue to own their GSK shares unless they sell or transfer them
in the ordinary course.
Following the Demerger, the total issued ordinary share capital of
Haleon will be held as follows:
● at least 54.5 per cent. will be held in aggregate
by GSK shareholders;
● up to 6 per cent. will be held by
GSK;
● 32 per cent. will be held by Pfizer;
and
● certain Scottish limited partnerships (the "SLPs")
set up to provide a funding mechanism pursuant to which GSK will
provide additional funding for GSK's UK Pension Schemes, will in
aggregate hold 7.5 per cent.
In addition to receiving cash from the Pre-Demerger Dividends, GSK
intends to monetise its holding in Haleon in a disciplined manner
to further strengthen the Company's balance sheet. GSK will
also have the ability to monetise the 7.5 per cent. holding of the
SLPs, and to retain any proceeds in excess of approximately
£1.08 billion (being the amount required to fully fund
the technical
provisions funding deficits of GSK UK Pension Schemes,
as determined
at the last triennial valuation). In keeping with Pfizer's
transformation into a more focused, global leader in science-based
innovative medicines and vaccines, Pfizer intends to exit its 32
per cent. ownership interest in Haleon in a disciplined
manner, with the objective of maximising value for Pfizer
shareholders.
Conditions to completion
The Demerger is conditional on, among other things, the approval by
GSK shareholders of the Demerger, the GSK Share Consolidation and
the Related Party Transactions at a General Meeting, the receipt of
all necessary mandatory governmental/regulatory approvals and the
final approval of the Demerger by the GSK Board.
Description of the Related Party Transactions
By virtue of Pfizer being a related party of GSK under the Listing
Rules as a result of its 32 per cent. interest in the Consumer
Healthcare business, the entry into certain new arrangements (or
amendments to certain existing arrangements) between GSK, Haleon
and Pfizer in connection with the Demerger and separation
constitute related party transactions for the purposes of Chapter
11 of the Listing Rules.
In particular, while various arrangements between GSK and Pfizer in
connection with the formation of the Consumer Healthcare joint
venture and separation were approved by GSK shareholders at a
general meeting of GSK on 8 May 2019 ("Shareholder-Approved
Arrangements"), material amendments to the Shareholder-Approved
Arrangements and certain new arrangements with Pfizer outside the
scope of these Shareholder-Approved Arrangements (and otherwise not
exempt under the Listing Rules) require Shareholder approval. These
related party transactions, which are aggregated in accordance with
Chapter 11 of the Listing Rules, require the approval of GSK
shareholders.
Specifically, the Related Party Transactions comprise:
Pfizer SAPA Amendment Agreement
GSK, Pfizer and Haleon have agreed to certain amendments to the
stock and asset purchase agreement dated 19 December 2018 and
amended and restated on 31 July 2019 between Pfizer, GSK,
GlaxoSmithKline Consumer Healthcare Holdings Limited and JVCo (the
"Pfizer SAPA"), including amendments:
●
to reflect the proposed separation of
the Haleon Group to operate as a business independent from the GSK
Group and the Pfizer Group;
●
that are required as a result of overlap with
certain other agreements to effect the proposed Demerger and the
proposed separation of the Haleon Group;
●
to update the liability framework
established by the Pfizer SAPA to reflect the proposed separation
of the Haleon Group.
Tax Covenant
Pfizer, GSK and Haleon have agreed to allocate tax risk associated
with the Demerger, and certain associated transactions and
reorganisation steps through indemnities from: (i) GSK and Pfizer
to Haleon; and (ii) from Haleon to each of GSK and
Pfizer.
Orderly Marketing Agreement
GSK, Pfizer and each of the SLPs have agreed to regulate sales of
interests in Haleon shares (including ADSs) by each of them,
including ensuring that when one party proposes to sell Haleon
shares the other parties have the opportunity to participate in any
such sale. The parties have undertaken not to sell any Haleon
shares without following the procedure set out in the Orderly
Marketing Agreement, which requires Pfizer to give notice to GSK
(where Pfizer and/or its associates are proposing to sell Haleon
shares) and GSK to give notice to Pfizer (where GSK, one or more of
the SLPs and/or their respective associates are proposing to sell
Haleon Shares) of any such proposed new sale of Haleon shares. The
extent to which each party is entitled to participate in any
proposed sale of Haleon shares notified to it, should it choose to
do so, is determined in accordance with an allocation mechanism
included in the agreement.
Lock-up Deed
Pfizer, GSK and each of the SLPs have agreed to a lock-up, being
the prohibition of offers, sales, loans, pledges or other
disposals of Haleon shares and ADSs in respect of Haleon shares by
GSK, Pfizer or the SLPs during the period commencing on completion
of the exchange transactions to establish the interests of each of
GSK, Pfizer and the SLPs in Haleon and ending on the day after the
earlier of: (i) 10 November 2022; and (ii) the release by Haleon of
a quarterly trading update in respect of a quarterly period ending
after 30 June 2022.
Pfizer Exchange Agreement
To establish its interest in Haleon, Pfizer has agreed to exchange
its ownership interest in PF Consumer Healthcare Holdings LLC (the
Pfizer Group subsidiary that holds direct ownership interests in
JVCo) for: (i) Haleon shares constituting in aggregate 32 per cent.
of Haleon's ordinary share capital at Admission; and (ii)
non-voting preference shares in Haleon.
NEBA Amendment Agreement
Pfizer and GSK have agreed to amend the terms of the original net
economic benefit letter agreement between Pfizer, GSK and JVCo
dated 31 July 2019. These amendments include changes to the
governance, operation and expected transfer timings of certain
businesses, assets, liabilities and employees that were included in
the original perimeter of the GSK/Pfizer joint venture as
contemplated in the Pfizer SAPA, but for certain regulatory and
other local market commercial reasons will not legally transfer
from the GSK Group to the Haleon Group until a date following the
Demerger.
Each of the above are described in further detail in paragraph 7 of
Part 7 (Additional
Information) of the
Circular.
Disclaimer
GSK makes no representation or warranty as to the appropriateness,
accuracy, completeness or reliability of the information in this
announcement.
This announcement is for information purposes only and is not
intended to and does not constitute or form part of any offer or
invitation to purchase, otherwise acquire, subscribe for, sell,
otherwise dispose of or issue, or any solicitation of any offer to
sell, otherwise dispose of, issue, purchase, otherwise acquire or
subscribe for, any security.
Prior to making any decision in relation to the Demerger,
shareholders should read the Circular and the Prospectus in their
entirety, including the information incorporated by reference.
Shareholders must rely upon their own examination, analysis and
enquiries of GSK and the terms of the Circular and Prospectus,
including the merits and risks involved.
Information regarding forward-looking statements
This announcement contains statements that are, or may be deemed to
be, "forward-looking statements". Forward-looking statements give
GSK's current expectations or forecasts of future events, including
strategic initiatives and future financial condition and
performance relating to Haleon and/or GSK. An investor can identify
these statements by the fact that they do not relate strictly to
historical or current facts. They use words such as 'anticipate',
'estimate', 'expect', 'intend', 'will', 'project', 'plan',
'believe', 'target', 'aim', 'ambition' and other words and terms of
similar meaning in connection with any discussion of future
operating or financial performance. In particular, these include
statements relating to future actions, plans, objectives, goals,
event or intentions. Other than in accordance with its legal or
regulatory obligations (including under the Market Abuse
Regulation, the UK Listing Rules and the Disclosure Guidance and
Transparency Rules of the Financial Conduct Authority), GSK
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reader should, however, consult any additional disclosures that
GSK may make in any documents which it publishes and/or files with
the SEC. All readers, wherever located, should take note of these
disclosures. Accordingly, no assurance can be given that any
particular expectation will be met and investors are cautioned not
to place undue reliance on the forward-looking
statements.
Forward-looking statements are subject to assumptions, inherent
risks and uncertainties, many of which relate to factors that are
beyond GSK's control or precise estimate. GSK cautions investors
that a number of important factors, including those in this
document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under Item
3.D 'Risk Factors' in GSK's Annual Report on Form 20-F for
2021, GSK's
Q1 Results for 2022 and
any impacts of the COVID-19 pandemic. Any forward-looking
statements made by or on behalf of GSK speak only as of the date
they are made and are based upon the knowledge and information
available to the directors on the date of this
announcement.
Assumptions
All outlooks, ambitions considerations in relation to GSK should be
read together with pages 5-7 of the Stock Exchange announcement
relating to an update to investors dated 23 June 2021 and the
Guidance, assumptions and cautionary statements of GSK's Q2 2021
earnings release.
In outlining the medium term outlooks and growth ambitions for
Haleon, GSK has made certain assumptions about the consumer
healthcare sector, the different geographic markets and product
categories in which Haleon operates and the delivery of revenues
and financial benefits from its current product range, pipeline and
integration and restructuring programmes. These assumptions, as
well as the outlooks, ambitions or considerations (as applicable)
for organic annual sales growth, adjusted operating margin
expansion, dividend payout ratio, cash generation/conversion and
deleveraging, assume, among other things, no material interruptions
to the supply of Haleon's products, no material mergers,
acquisitions or disposals, no material litigation or investigation
costs (save for those that are already recognised or for which
provisions have been made), no material changes in the regulatory
framework for developing new products and retaining marketing
approvals, no material changes in the healthcare environment, no
unexpected significant changes in Haleon's end markets, no
unexpected significant changes in pricing as a result of
government, customer or competitor action, no unexpected
significant geopolitical developments, no material changes in
foreign currency exchange rates and no material changes in the
impacts of the COVID-19 pandemic. These outlooks, ambitions and
considerations also assume the successful delivery of the
separation programme to deliver the demerger of Haleon and the
realisation of its anticipated benefits. The outlook and growth
ambitions are given at constant exchange rates.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7823 523562
|
(Consumer)
|
|
|
Emma
White
|
+44 (0)
7823 523562
|
(Consumer)
|
|
|
Rakesh
Patel
|
+44 (0)
7552 484646
|
(Consumer)
|
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[1] It
is expected that Haleon ADSs will commence "regular-way" trading on
the NYSE at market open on 22 July 2022. In addition, we expect
that Haleon ADSs will begin trading on a "when-issued" basis on the
NYSE from market open on 18 July 2022 up to and including 21 July
2022.
[2] This
pro forma financial information is unaudited. It has been prepared
on the basis of the unaudited interim financial information of
Haleon as at 31 March 2022, the date to which the latest unaudited
financial information in relation to Haleon was prepared. This pro
forma information is shown for illustrative purposes only and
because of its nature addresses a hypothetical situation. It does
not represent Haleon's actual financial position or results. It may
not, therefore, give a true picture of Haleon's financial position
or results nor is it indicative of the results that may, or may
not, be expected to be achieved in the future. Please refer to the
Prospectus for further details.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: June
01, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|